Lateral Flow Assay Fundamentals: How Rapid Tests Work

Added:

The Limits of Lateral Flow: The Case for Microfluidics and Molecular Diagnostics

While lateral flow assays (LFAs) are highly valued for their low cost, simplicity, and rapid results, critics emphasize their inherent technical limitations compared to alternative diagnostic platforms. The primary drawback of LFAs is their relatively low analytical sensitivity and specificity, which can lead to false-negative results during early stages of infection when analyte concentrations are low. Furthermore, LFAs are typically qualitative or only semi-quantitative, lacking the precision needed for complex monitoring. To overcome these limitations, many researchers and clinicians advocate for point-of-care microfluidic "lab-on-a-chip" devices and isothermal nucleic acid amplification technologies (such as LAMP). These alternative platforms combine the speed and portability of rapid tests with the high sensitivity, quantification, and multiplexing capabilities of laboratory-based PCR. This perspective argues that relying solely on traditional paper-based chromatography compromises diagnostic accuracy, and that the future of rapid testing lies in advanced microfluidic and molecular technologies.

Basic immunology, specifically the structure of antibodies and the high specificity of antigen-antibody binding.
The physical principle of capillary action and how fluids transport through porous materials like nitrocellulose membranes.
Fundamental assay formats, particularly the difference between a sandwich assay and a competitive assay.
The role of signal reporters, such as colloidal gold nanoparticles or fluorescent beads, in visual detection.
Multiplexed lateral flow assays designed to detect multiple analytes from a single sample simultaneously.
Quantitative lateral flow technologies that use optical or digital strip readers rather than simple visual inspection.
Industrial manufacturing and quality control standards for diagnostic devices, including reagent stability and strip lamination.
Nucleic Acid Lateral Flow Assays (NALFAs) and their combination with rapid molecular amplification methods like LAMP or CRISPR.
Troubleshooting assay limitations, such as mitigating the Hook effect, cross-reactivity, and matrix interference in clinical samples.
36.2K views0likes10:21@dcndiagnostics478Original Release: 2020-04-14

Lateral flow devices are rapid diagnostic tests that detect specific analytes through a sandwich immunoassay mechanism, where capture antibodies immobilized on a nitrocellulose membrane bind to target antigens in a sample, and detector antibodies conjugated with visual particles (like gold nanoparticles) form a visible line when they bind to the captured antigen; the manufacturing process involves preparing antibody solutions, dispensing capture antibodies onto membrane strips to create test and control lines, spraying detector antibodies onto conjugate pads, and assembling these components with wick pads into a cassette format that allows untrained users to perform tests by applying samples and reading results within 10 minutes.